- Home
- NUVL vs GNTX Comparison
NUVL vs GNTX Comparison
Compare NUVL & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GNTX
- Stock Information
- Founded
- NUVL 2017
- GNTX 1974
- Country
- NUVL United States
- GNTX United States
- Employees
- NUVL 200
- GNTX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GNTX Auto Parts:O.E.M.
- Sector
- NUVL Health Care
- GNTX Consumer Discretionary
- Exchange
- NUVL Nasdaq
- GNTX Nasdaq
- Market Cap
- NUVL 6.0B
- GNTX 6.1B
- IPO Year
- NUVL 2021
- GNTX N/A
- Fundamental
- Price
- NUVL $83.09
- GNTX $26.56
- Analyst Decision
- NUVL Strong Buy
- GNTX Buy
- Analyst Count
- NUVL 9
- GNTX 7
- Target Price
- NUVL $118.89
- GNTX $29.29
- AVG Volume (30 Days)
- NUVL 396.7K
- GNTX 1.9M
- Earning Date
- NUVL 11-11-2025
- GNTX 10-24-2025
- Dividend Yield
- NUVL N/A
- GNTX 1.80%
- EPS Growth
- NUVL N/A
- GNTX N/A
- EPS
- NUVL N/A
- GNTX 1.77
- Revenue
- NUVL N/A
- GNTX $2,384,794,644.00
- Revenue This Year
- NUVL N/A
- GNTX $11.01
- Revenue Next Year
- NUVL N/A
- GNTX $6.50
- P/E Ratio
- NUVL N/A
- GNTX $15.01
- Revenue Growth
- NUVL N/A
- GNTX 2.43
- 52 Week Low
- NUVL $55.54
- GNTX $20.28
- 52 Week High
- NUVL $106.32
- GNTX $31.48
- Technical
- Relative Strength Index (RSI)
- NUVL 56.32
- GNTX 32.74
- Support Level
- NUVL $81.02
- GNTX $27.95
- Resistance Level
- NUVL $86.34
- GNTX $29.01
- Average True Range (ATR)
- NUVL 3.63
- GNTX 0.49
- MACD
- NUVL 0.28
- GNTX -0.26
- Stochastic Oscillator
- NUVL 66.33
- GNTX 0.58
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.